Vifor to distribute Debiopharm's Pamorelin in Switzerland

Swiss independent drug developer Debiopharm) and Switzerland-based Vifor Pharma – part of Galenica (SIX: GALN) – have signed an exclusive agreement covering the distribution and commercialization in Switzerland of the one-, three- and six-month formulations of Pamorelin LA and Salvacyl a three-month formulation of the gonadotropin releasing hormone agonist analog triptorelin.

Pamorelin LA, which contains the active substance triptorelin in the form of pamoate salt, is indicated for the treatment of advanced hormone-dependent prostate cancer, endometriosis and female infertility. Salvacyl is indicated for the treatment of severe sexual deviation in men. The one and three month formulations of Pamorelin LA are available immediately, while the introduction of the six-month Pamorelin LA and Salvacyl will be communicated by Vifor Pharma at a later date.

Developed by Debiopharm, both the products are manufactured by Debio RP in Martigny, Debiopharm's site for applied research, controlled release formulation development and production.